Search Results for: RELA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
NR3C1 nuclear receptor subfamily 3 group C member 1
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Circadian Clock
  • SUMOylation of intracellular receptors
  • PTK6 Expression
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol acetate
  • Levonorgestrel
  • Beclomethasone dipropionate
  • Progesterone
  • Spironolactone
  • Betamethasone
  • Desoximetasone
  • Fluticasone propionate
  • Fluocinolone acetonide
  • Ulobetasol
  • Triamcinolone
  • Prednisone
  • Flumethasone
  • Fludrocortisone
  • Norethisterone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol etabonate
  • Rimexolone
  • Methylprednisolone
  • Clobetasol propionate
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Drospirenone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Aldosterone
  • ORG-34517
  • Difluprednate
  • Ulipristal
  • Fluticasone furoate
  • Tixocortol
  • Difluocortolone
  • Gestrinone
  • Deflazacort
  • Onapristone
  • Cortivazol
  • Clobetasone
  • Fluticasone
  • Mometasone furoate
  • Hydrocortisone aceponate
  • Hydrocortisone acetate
  • Hydrocortisone butyrate
  • Hydrocortisone cypionate
  • Hydrocortisone phosphate
  • Hydrocortisone probutate
  • Hydrocortisone valerate
  • Segesterone acetate
  • Prednisolone phosphate
  • Dexamethasone acetate
  • Betamethasone phosphate
  • Prednisolone acetate
  • 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
PARP1 poly(ADP-ribose) polymerase 1
  • POLB-Dependent Long Patch Base Excision Repair
  • vRNA Synthesis
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SUMOylation of DNA damage response and repair proteins
  • HDR through MMEJ (alt-NHEJ)
  • DNA Damage Recognition in GG-NER
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • Theophylline
  • Zinc
  • Carba-nicotinamide-adenine-dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • Veliparib
  • A-620223
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
  • Olaparib
  • Talazoparib
  • Niraparib
  • Rucaparib
  • Iniparib
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
PDCD11 programmed cell death 11
  • rRNA modification in the nucleus and cytosol
  • Major pathway of rRNA processing in the nucleolus and cytosol
PGR progesterone receptor
  • Nuclear signaling by ERBB4
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Estrogen-dependent gene expression
  • Etonogestrel
  • Desogestrel
  • Megestrol acetate
  • Levonorgestrel
  • Dydrogesterone
  • Progesterone
  • Spironolactone
  • Lindane
  • Fluticasone propionate
  • Medroxyprogesterone acetate
  • Mitotane
  • Norethisterone
  • Mometasone
  • Ethynodiol diacetate
  • Mifepristone
  • Norgestimate
  • Drospirenone
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Phthalic Acid
  • Metribolone
  • Tanaproget
  • Telapristone acetate
  • Asoprisnil
  • Norelgestromin
  • Gestodene
  • Hydroxyprogesterone caproate
  • Ulipristal
  • Fluticasone furoate
  • Dienogest
  • Medrogestone
  • Norgestrel
  • Homosalate
  • Enzacamene
  • Gestrinone
  • Darolutamide
  • Demegestone
  • Fluticasone
  • Mometasone furoate
  • Segesterone acetate
PIAS1 protein inhibitor of activated STAT 1
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of intracellular receptors
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • Formation of Incision Complex in GG-NER
  • Regulation of IFNG signaling
PIAS3 protein inhibitor of activated STAT 3
  • SUMOylation of transcription factors
  • SUMOylation of transcription cofactors
  • SUMOylation of intracellular receptors
  • SUMOylation of DNA replication proteins
  • SUMOylation of immune response proteins
  • Formation of Incision Complex in GG-NER
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1
  • ISG15 antiviral mechanism
  • RHO GTPases Activate NADPH Oxidases
  • Regulation of TP53 Activity through Phosphorylation
  • PI5P Regulates TP53 Acetylation
  • Negative regulators of DDX58/IFIH1 signaling
  • Beta-(2-Naphthyl)-Alanine
  • 3,6,9,12,15,18-HEXAOXAICOSANE
PKM pyruvate kinase M1/2
  • Neutrophil degranulation
  • Pyruvic acid
  • L-Phospholactate
  • 2-Phosphoglycolic Acid
  • 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
  • 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
  • 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
  • Copper
  • Artenimol
PLA2G4A phospholipase A2 group IVA
  • phospho-PLA2 pathway
  • Acyl chain remodelling of PC
  • Acyl chain remodeling of CL
  • Acyl chain remodelling of PS
  • Acyl chain remodelling of PE
  • Acyl chain remodelling of PI
  • Acyl chain remodelling of PG
  • Hydrolysis of LPC
  • Synthesis of PA
  • Arachidonic acid metabolism
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • COPI-independent Golgi-to-ER retrograde traffic
  • Fluticasone propionate
  • Procaine
  • Quinacrine
  • Niflumic acid
  • Darapladib
  • Fluticasone
PLK1 polo like kinase 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • Mitotic Metaphase/Anaphase Transition
  • Mitotic Telophase/Cytokinesis
  • Cyclin A/B1/B2 associated events during G2/M transition
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
  • 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
  • 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
  • Wortmannin
  • Fostamatinib
PML PML nuclear body scaffold
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Regulation of TP53 Activity through Acetylation
  • Interferon gamma signaling
  • Regulation of RUNX1 Expression and Activity
  • Regulation of PTEN localization
  • HCMV Early Events
  • Arsenic trioxide
  • Acute myeloid leukemia (AML)
POU2F1 POU class 2 homeobox 1
  • Interleukin-4 and Interleukin-13 signaling
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • Estrogen-dependent gene expression
POU6F2 POU class 6 homeobox 2
PPARA peroxisome proliferator activated receptor alpha
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • SUMOylation of intracellular receptors
  • alpha-Linolenic acid
  • Icosapent
  • Troglitazone
  • Valproic acid
  • Indomethacin
  • Rosiglitazone
  • Fenoprofen
  • Clofibrate
  • Fenofibrate
  • Ibuprofen
  • Amiodarone
  • Gemfibrozil
  • Bezafibrate
  • Prasterone
  • N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide
  • Flufenamic acid
  • Resveratrol
  • Phthalic Acid
  • Lauric acid
  • Stearic acid
  • Doconexent
  • Palmitic Acid
  • Oleic Acid
  • Caprylic acid
  • Arachidonic Acid
  • Reglitazar
  • Elafibranor
  • Cardarine
  • Muraglitazar
  • Ertiprotafib
  • Ragaglitazar
  • Tesaglitazar
  • GW-590735
  • Indeglitazar
  • Myristic acid
  • Aleglitazar
  • Clinofibrate
  • Ciprofibrate
  • Dexibuprofen
  • Soybean oil
  • Omega-3 fatty acids
  • Myrrh
  • Isoflavone
  • Leukotriene B4
  • Fenofibric acid
  • Fish oil
PPARG peroxisome proliferator activated receptor gamma
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • MECP2 regulates transcription factors
  • alpha-Linolenic acid
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Valproic acid
  • Indomethacin
  • Rosiglitazone
  • Fenoprofen
  • Nateglinide
  • Sulfasalazine
  • Clofazimine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Amiodarone
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • Flufenamic acid
  • Resveratrol
  • Phthalic Acid
  • Capric acid
  • Doconexent
  • Oleic Acid
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • Reglitazar
  • Elafibranor
  • AMG-131
  • CLX-0921
  • Muraglitazar
  • Ertiprotafib
  • Ragaglitazar
  • Tesaglitazar
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • 9(S)-HODE
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • Indeglitazar
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • Triclosan
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • Aleglitazar
  • Clinofibrate
  • Cannabidiol
  • Lobeglitazone
  • Ciglitazone
  • Dexibuprofen
  • Omega-3 fatty acids
  • Curcumin
  • Arhalofenate
  • Isoflavone
  • Naveglitazar
  • Fenofibric acid
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Darglitazone
  • Curcumin sulfate
  • Type II diabetes mellitus
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Thyroid cancer
PPP1R13L protein phosphatase 1 regulatory subunit 13 like
  • Regulation of TP53 Activity through Association with Co-factors
PPP2CA protein phosphatase 2 catalytic subunit alpha
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Spry regulation of FGF signaling
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Integration of energy metabolism
  • PP2A-mediated dephosphorylation of key metabolic factors
  • DARPP-32 events
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • ERK/MAPK targets
  • ERKs are inactivated
  • MASTL Facilitates Mitotic Progression
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Initiation of Nuclear Envelope (NE) Reformation
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • EML4 and NUDC in mitotic spindle formation
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Vitamin E
  • 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
  • (2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid
PPP2CB protein phosphatase 2 catalytic subunit beta
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Spry regulation of FGF signaling
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Integration of energy metabolism
  • PP2A-mediated dephosphorylation of key metabolic factors
  • DARPP-32 events
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • ERK/MAPK targets
  • ERKs are inactivated
  • MASTL Facilitates Mitotic Progression
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • EML4 and NUDC in mitotic spindle formation
  • Vitamin E
PPP2R1B protein phosphatase 2 scaffold subunit Abeta
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Integration of energy metabolism
  • PP2A-mediated dephosphorylation of key metabolic factors
  • DARPP-32 events
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • ERK/MAPK targets
  • ERKs are inactivated
  • MASTL Facilitates Mitotic Progression
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • EML4 and NUDC in mitotic spindle formation

Page 7 out of 11 pages